Puma Biotechnology, Inc.

NASDAQ:PBYI

Biotechnology

Healthcare
$7.22 +2.21%

+$0.16 today

Market cap
$373.26M
Beta
1.21
P/E (TTM)
15.4
EPS (TTM)
$0.48
52W Low $3.03High $7.90

Volume 0.45M

Average 0.26M

PBYI Interest Expense

Cost of servicing the company's debt during the period.

Puma Biotechnology, Inc.NASDAQ: PBYI

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense declines year over year

Q1 FY2026 interest expense of $731K fell 66.4% year over year, behind the -54.1% change in trailing-twelve-month interest expense. Sequentially, it fell 34.7% from the prior quarter. Over 3 fiscal years it compounded at -17.0% a year.

Context

  • Interest expense amounted to 2.9% of revenue in FY2025, down 2.5 pp from a year earlier.
  • Interest expense increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -66.4% toward the trailing-twelve-month pace of -54.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$731K-34.7% QoQ
Last fiscal yearDec 2025
$6.62M-46.8% YoY
LTMMar 2026
$5.18M-54.1% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-66.4%——
1 year-46.8%——
3-year CAGR-17.0%——
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
6.62M USD
Year-over-year change
-46.8%
4-year CAGR
-15.2%

Interest Expense vs competitors

How PBYI compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -54.1% is the 3rd highest of 4, against a peer median of +3799.7%.
  • Interest expense amounts to 2.3% of revenue for PBYI, versus a peer median of 5.6%.
PBYI Competitors
Interest Expense for PBYI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NUVBNuvation Bio Inc.LTM Jun 2026$26.67M USD+3799.7%—15.7%
MGNXMacroGenics, Inc.LTM Mar 2026$13.31M USD+13616.5%—8.5%
PBYIPuma Biotechnology, Inc.LTM Mar 2026$5.18M USD-54.1%-17.0%2.3%
VSTMVerastem, Inc.LTM Mar 2026$1.33M USD-63.4%-18.9%2.7%
TNGXTango Therapeutics, Inc.LTM Sep 2026$0 USD———
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$0 USD———
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$0 USD———
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026$0 USD———
CRDFCardiff Oncology, Inc.LTM Mar 2026$0 USD——0.0%
NBPNovaBridge BiosciencesLTM Sep 2025CN¥0 CNY———
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$0 CAD———
Peer median (excluding PBYI) —+3799.7%-18.9%5.6%

Competitors are the stored peer set for PBYI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue253.16M228.03M235.64M230.47M228.37M
Cost of Revenue63.7M55.09M62.68M64.4M58.16M
Gross Profit189.45M172.94M172.96M166.06M170.21M
Gross Margin74.8%75.8%73.4%72.1%74.5%
Research & Development71.87M52.24M50.38M54.94M62.07M
Selling, General & Admin116.29M89.98M89.31M80.16M71.21M
Operating Expenses188.16M149.22M140.32M135.1M132.92M
Depreciation & Amortization11.31M9.84M11.52M11.52M10.94M
EBITDA(4.69M)21.89M47.52M48.08M53.34M
EBITDA Margin-1.9%9.6%20.2%20.9%23.4%
Operating Income1.29M23.72M32.64M30.97M37.3M
Operating Margin0.5%10.4%13.9%13.4%16.3%
Interest Income160K813K2.61M4.72M4.08M
Interest Expense12.81M11.59M13.33M12.45M6.62M
Other Income / Expenses(30.09M)(23.26M)(9.97M)(6.87M)(1.52M)
Income Before Tax(28.8M)457K22.67M24.1M35.78M
Pre-Tax Margin-11.4%0.2%9.6%10.5%15.7%
Income Tax Expense324K455K1.08M(6.18M)4.67M
Net Income(29.13M)2K21.59M30.28M31.11M
Net Margin-11.5%0.0%9.2%13.1%13.6%
EPS (Basic)(0.72)0.020.460.620.62
EPS (Diluted)(0.72)0.020.450.620.61
Weighted Avg Shares40.64M44.67M47.13M48.65M50.01M
Weighted Avg Shares (Diluted)40.64M44.93M47.55M49.1M50.65M

Puma Biotechnology, Inc.

NASDAQ:PBYI

Intrinsic Alpha fair value

Locked

Current Price

$7.22

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.